由孕妇X受体引起的骨髓瘤药物耐药性的进展
Kunhong Mao1, Can Liu2, Zhongwen Tang3
1Key Laboratory of Translational Cancer Stem Cell Research, Department of Physiology, Hunan Normal University School of Medicine, Changsha, China.
Drug metabolism reviews
|June 14, 2024
概括
孕妇X受体 (PXR) 可能在骨髓瘤 (OS) 中驱动化疗耐药性. 了解PXR的理解
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓瘤 (OS) 是一种常见的青少年癌症,具有高恶性和转移潜力.
- 化疗对OS有效,但耐药性仍然是一个重大的临床挑战.
- 了解化疗耐药性的机制对于改善OS治疗结果至关重要.
研究的目的:
- 审查Pregnane X受体 (PXR) 在骨髓瘤化疗耐药性中的作用.
- 探索PXR如何影响OS中的药物代谢,运输和消除.
主要方法:
- 文献综述专注于研究研究PXR表达和功能在骨髓瘤.
- 分析PXR在异生物代谢,药物结合酶和药物运输体中的参与.
- 检查OS中增加PXR表达和观察到的耐药性之间的相关性.
主要成果:
- 孕妇X受体 (PXR) 与各种恶性瘤的化疗耐药性有关.
- 在骨髓瘤中观察到PXR表达的升高.
- 在OS中增加的PXR水平可能与对化疗剂敏感性降低有关.
结论:
- 孕妇X受体 (PXR) 在骨髓瘤中介化疗耐药性方面发挥着重要作用.
- 向PXR可能提供一种新的治疗策略,以克服OS患者的耐药性.
- 进一步研究PXR在OS中的机制是有必要的,以开发更有效的治疗方案.
更多相关视频
07:31A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
3.6K
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
12.8K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
